日期: 2026年2月6日

Hong Kong, Feb. 6, 2026 - (ACN Newswire via SeaPRwire.com) - Viva World Trade, Inc. ("VVWT" or the "Company"; OTCID:VVWT) is pleased to announce that Mr. Liu Xiaojun, on behalf of Fufeng Group ("Fufeng Group"; HK:00546), has successfully completed the full acquisition of the Company. This acquisition has fulfilled all necessary internal decision-making procedures and relevant regulatory requirements of OTC Markets. The transfer of equity and handover of control have been fully completed, and Mr. Liu Xiaojun, representing Fufeng Group, has formally become the sole controlling shareholder of the Company.Fufeng Group, established in Hong Kong in 2021, is a comprehensive multinational conglomerate focusing on four core business segments: international investment, cross-border trade, compliant crypto asset services, and global business agency. It is committed to providing integrated cross-border development solutions for enterprises through a dual-engine approach of "real industries + financial capital."Upholding the core operating philosophy of "Integrity, Professionalism, and Win-Win Cooperation," the Group has established multiple offices within China, building a diversified industrial ecosystem to precisely connect with premium global project resources and empower enterprises in achieving cross-border development and value enhancement. Notably, the Inner Mongolia Yellow Cattle Breeding Project (spanning 2,400 acres) has completed all preliminary preparations and is poised to enter large-scale operation, injecting robust growth momentum into the Group's real industry sector.Guided by the development logic of "industry empowering capital, capital driving industry," Fufeng Group has established its core strategic positioning: anchored in compliant operations, leveraging cross-border M&A and asset integration to facilitate the Nasdaq Main Board listing of its subsidiary Viva World Trade, Inc., thereby launching a new chapter in global capital operations.Future Planning and Strategic Deployment (Through Q1 2026)To accelerate the realization of the Group's overall strategic objectives, Fufeng Group has outlined clear directives for its affiliated entity Viva World Trade, Inc., planning to complete the following key strategic steps by the end of March 2026:1. Advance Crypto Asset Strategic Integration: By late February 2026, negotiate and execute a "triangular reverse merger transaction" with a leading crypto-native asset company. This aims to efficiently integrate innovative value from cutting-edge digital asset sectors, injecting fresh growth momentum into the Group.2. Introduce Professional Capital Services Partner: By late March 2026, establish deep cooperation with a professional investment institution possessing extensive market experience. This partnership will assist the company in global market expansion, enhance compliance operations to increase market visibility and capital allocation efficiency, and solidify the foundation of corporate value.3. Secure NASDAQ Listing Pathway: By the end of March 2026, the company plans to engage a professional advisory firm with expertise in U.S. stock market listings. A dedicated listing advancement team will be established to formally initiate preparations for a NASDAQ Main Board listing, laying a solid foundation for compliance filings and the transition to the main board.Viva World Trade, Inc. on OTC Markets: https://www.otcmarkets.com/stock/VVWT/profileForward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on management's current plans and expectations and are subject to various uncertainties and risks that could materially affect the company's current plans and expectations, as well as its future operating results and financial condition. For a more detailed list of risks and factors that could affect the Company's business prospects and cause actual results to differ materially from those described in forward-looking statements, please refer to the Company's reports and other filings with the U.S. Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Please contact:GEMZ CORPhyxinvest@yeah.net  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672. HK). GIC purchased 64,128,000 shares at an average price of approximately HK$12.18 per share, representing a total investment of roughly HK$781 million (approx. US$100 million). This transaction marks the official entry of one of the world's leading sovereign funds into Ascletis Pharma's shareholder base, drawing market attention to the renewed positioning of global long-term capital in China's innovative pharmaceutical sector.As one of the most representative sovereign funds globally, GIC's investment decisions highly emphasize certainty and the ability to navigate economic cycles. Its continuous increase in holdings in a single target usually means that its mid-to-long-term value judgment on the relevant assets has become clear. Unlike tactical transactions by short-term funds, GIC focuses more on whether the industrial logic is sound, whether R&D realization has time visibility, and the potential returns over the next few years.From a portfolio allocation perspective, GIC's decision to invest in Ascletis Pharma also reflects, to a certain extent, its recognition of the company's BD capabilities and pipeline structure. Ascletis Pharma's strategic layout in the innovative drug field exhibits differentiated characteristics, with a clear R&D pace. Its pipeline structure highly matches the "long-term, verifiable innovation" standards preferred by sovereign funds.As of now, GIC holds 64,128,000 shares of Ascletis Pharma, accounting for approximately 6.42% of the company's issued share capital (calculated based on 1,068,214,530 issued shares).Overall, GIC's current investment is more a strategic continuation of its presence in the Hong Kong innovative drug sector, rather than a short-term speculative behavior. As long-term capital gradually returns to fundamental pricing, core targets with genuine BD capabilities are re-entering the allocation scope of international capital. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 2026年2月6日报道，根据香港联交所2月6日披露的文件，新加坡政府投资公司（GIC Private Limited）于2月5日首次入股歌礼制药（01672），以每股均价12.18 港元 买入 64,128,000 股普通股股份，合计涉资约7.81 亿港元，折合约1亿美元。入股完成后，GIC持有歌礼制药64,128,000股股份，占公司已发行股本约6.42%，正式跻身公司主要机构股东行列。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.From a clinical value perspective，VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.“UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”“Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”“Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.Industry observers widely expect VELSIPITY(R) to become Everest's next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest's revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，中国国家药品监督管理局（NMPA）已批准维适平(R)（精氨酸艾曲莫德片, VELSIPITY(R)）的新药上市许可申请（NDA），用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。溃疡性结肠炎是一种病因尚不明确、易复发的慢性肠道炎症性疾病。近年来，中国溃疡性结肠炎发病率持续上升，并呈现年轻化趋势，预计患者人数将由2025年的约98万增长至2031年的约150万。疾病对患者生活质量带来长期负担，临床亟需实现更加稳定、持久的疾病控制。作为新一代高选择性S1P受体调节剂，维适平(R)每日一次口服，可实现快速起效和强效深度黏膜愈合，并具有良好的安全性特征，具备最佳药物（best-in-disease）潜质，为成人溃疡性结肠炎患者提供新的一线治疗选择。据悉，维适平(R)此次获批，是基于亚洲多中心III期注册临床ENLIGHT UC研究（ES101002）的结果和全球III期注册研究ELEVATE UC（包括ELEVATE UC 52和ELEVATE UC 12研究）的结果。ENLIGHT UC研究是迄今完成的最大规模亚洲中重度活动性溃疡性结肠炎患者的III期注册临床研究，总计纳入340名患者。结果显示，维适平(R)治疗组在所有主要和次要疗效终点上均达到统计学显著性与临床意义，且安全性良好。研究结果已发表于国际顶级学术期刊柳叶刀子刊《The Lancet Gastroenterology & Hepatology》。从临床价值来看，维适平(R)凭借每日一次口服的治疗方案，能够快速起效并达到临床缓解，同时还在黏膜愈合和组织学改善等方面疗效显著，同时安全性良好。对此，中华医学会消化病学分会前任主任委员、炎症性肠病学组组长、中山大学附属第一医院消化内科学术带头人、首席专家陈旻湖教授指出，我国目前正处于溃疡性结肠炎发病率和患病率快速上升阶段，该疾病常反复发作，严重影响患者生活质量，对个人、家庭和医疗资源造成沉重负担。实现黏膜愈合有助于更有效地控制症状，降低复发风险，改善患者生活质量。黏膜愈合是国内外临床指南公认的溃疡性结肠炎治疗目标，这不仅关系到疾病的长期症状缓解，也与改善患者生活质量密切相关。维适平(R)亚太临床试验牵头研究者、世界胃肠病组织执委兼司库、亚太地区消化病学会副主席、中华医学会消化病学分会第十、十一届副主委、空军军医大学西京消化病医院吴开春教授指出，长期以来，我国溃疡性结肠炎治疗面临传统疗法疗效有限、给药便捷性差以及不良反应多等诸多局限。已获批的生物制剂和小分子治疗也存在"疗效天花板"及"失应答"等问题。维适平(R)通过调控淋巴细胞迁移，从源头控制肠道炎症，并促进黏膜愈合。在多个临床研究中维适平(R)展现出显著疗效，尤其在快速起效、实现无激素缓解及深度黏膜愈合方面具有明显临床优势。此次获批标志着维适平(R)从临床研究到上市的完整验证，为患者提供创新治疗选择，并推动中重度溃疡性结肠炎管理进入新阶段。云顶新耀董事会主席吴以芳表示："自身免疫性疾病在全球范围内对患者造成长期而深远的影响，在中国乃至全球范围内，仍存在大量尚未满足的临床需求。维适平(R)的获批不仅体现了创新疗法在溃疡性结肠炎治疗中的临床价值，也彰显了公司坚持以国际研发标准推进创新药物发展的长期战略。我们期待通过持续拓展全球化布局，让更多患者受益于高质量、具有突破性的治疗选择。"云顶新耀首席执行官罗永庆表示: "此次维适平(R)在中国的获批，填补了中重度溃疡性结肠炎治疗领域的重要空白，并为以深度黏膜愈合为目标的创新口服治疗提供了新的选择。公司将加快推进维适平(R)的商业化进程，并积极推动纳入国家医保目录，持续提升创新疗法在中国的可及性和可负担性，让更多患者受益。"值得一提的是，维适平(R)的临床价值已获得多项国际权威指南的充分认可，被先后纳入2024年美国胃肠病协会（AGA）临床实践指南及2025年美国胃肠病学院（ACG）临床指南，并获强烈推荐。此前，该药已于2024年和2025年被列入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（文件中名称为"伊曲莫德"）。目前，维适平(R)已在美国、欧盟以及中国大陆、中国香港、中国澳门、新加坡等多个国家和地区获得新药上市批准。2025年3月，云顶新耀启动维适平(R)嘉善工厂建设项目，为本地化生产及长期可及性提供有力支持。维适平(R)的成功获批，进一步夯实了云顶新耀在自身免疫疾病领域的产品布局，也是公司2030年发展战略的重要组成部分。该战略以"BD合作 + 自主研发"双轮驱动为核心，致力于通过商业化实现确定性价值，同时通过持续创新研发构建长期成长动能，推动管线的延续性与可持续发展。在商业化平台建设上，云顶新耀已布局三款商业化产品，并着力建立全渠道商业化体系及药品全生命周期商业化能力。计划到2028年实现收入规模超过100亿元人民币，而到2030年收入规模超过150亿元人民币（其中现有管线销售收入约90亿元人民币而新引进管线销售收入约60亿元人民币）；收入的年复合增长率预计在2025至2030年超过50%，2030年后保持超过15%。同时，商业化产品数量将提升至20款以上，包括耐赋康(R)、维适平(R)、依嘉(R)、乐瑞泊(R)（莱达西贝普）及MT1013等。业内普遍认为，维适平(R)有望成长为云顶新耀又一重磅产品，其销售峰值预计可达50亿元人民币。随着维适平(R)商业化进程的持续推进，公司整体收入结构与成长曲线有望进一步优化。未来，云顶新耀将继续聚焦重大未满足临床需求，持续强化差异化创新管线，加速推进具有国际竞争力的创新疗法落地，助力公司实现可持续成长，并为患者与社会创造更大的健康价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Eternal Beauty Holdings Limited (“Eternal Beauty” or the “Group”) (Stock Code: 6883.HK), a pioneer in China’s beauty and fragrance industry, announced its first-ever collaboration with Lane Crawford, a premier luxury department store, to launch an exclusive boutique niche fragrance section at its Harbour City store in Tsim Sha Tsui. The collaboration aims to further advances the Group’s strategy focused on high-margin niche fragrance brands, strengthens its premium brand footprint through an elite retail network, and captures the growing profit opportunities in the niche fragrance for Chinese Mainland and Hong Kong markets.The zone brings together four international niche fragrance brands under the immersive concept of a "Luxury Niche Perfume Street" with European flair, featuring Atkinsons, Clive Christian, Memo Paris and SOLFÉRINO, each presented with its unique style and heritage. Clive Christian and SOLFÉRINO are making their debut in Hong Kong, offering a rare experience to local high-end consumers. By leveraging Lane Crawford’s premium retail network that reaches high-spending customers, the Group effectively enhances brand penetration in the Hong Kong market. This initiative successfully introduces the Group’s portfolio into a core upscale retail destination in Hong Kong, demonstrating the Group’s strengths in channel expansion and retail curation, while further solidifying its brand influence and long-term growth momentum in the niche fragrance portfolio.Brand Introduction:AtkinsonsThe 200-year-old British "Royal Fragrance House" reinvents the rebellion and elegance of 19th-century English gentlemen, transforming historical formulas into a modern, contemporary aura.Clive ChristianThe first exclusive collectors’ boutique in Hong Kong: Clive Christian is a luxury British perfume house that creates the world's finest perfumes. A legacy of British craftsmanship, unparalleled quality in concentration and complexity, unashamedly indulgent and luxurious presentation.Memo ParisMemo Paris is a Parisian fragrance house, see each fragrance as a travel note captured in scent. Preserve memory of a journey to unique destination. Memo Paris sketches a delicate, emotional map of the world: a universe where memories become scents.SOLFÉRINODebuting brilliantly in Hong Kong, SOLFÉRINO is born in Paris, France, the brand draws inspiration from the historic architecture of this City of Lights, showcases French elegance with exceptional craftsmanship and presenting Parisian audacity and creativity.Ms. Wendy Lau, Executive Director of Eternal Beauty and Chairman of the International Fragrance Association, said, “With over 40 years of industry experience, Eternal Beauty has cultivated sharp market vision, distinctive taste, and profound expertise. This enables the Group to accurately identify and introduce brands that align with market trends and carry strong profit potential into the Greater China market, which continues to demonstrate vigorous consumption upgrade momentum. We are thrilled to partner with Lane Crawford, an influential luxury department platform in Asia, to create this exclusive boutique niche fragrance section in Hong Kong’s core luxury shopping district, leveraging the Group’s strengths in niche fragrance brand management and retail channel development. This is not only an important step for the Group to deepen the niche fragrance market, but also a concrete manifestation of our niche fragrance brand expansion strategy. Moving forward, the Group will continue to explore collaborations with top-tier retail partners. By introducing more niche brands with high growth potential, it will strengthen its long-term growth momentum and enhance sustainable profitability in the fragrance market.”Hong Kong's fragrance market continues to benefit from the momentum of the emotional economy, demonstrating relatively resilient growth against the backdrop of a steady recovery in the overall retail sector. In December 2025, the value of total retail sales in Hong Kong increased by 6.6% YoY; according to market’s outlook reports, the total retail sales in Hong Kong are expected to grow by nearly 8% in 2026, reaching approximately HKD 410 billion, indicating a continued recovery in local consumer demand. Ms. Chole Lam, Executive Director and Chief Executive Officer of Eternal Beauty, said, “In recent years, experiential retail and emotional consumption have gradually emerged as new retail trends, with emotional value playing an increasingly significant role in consumer decision-making. The ability to establish emotional resonance with consumers is becoming an important direction for brand expansion and product innovation. Emerging consumption segments, represented by high-end and niche fragrances, are more being regarded as categories that carry emotional value and lifestyle propositions, highlighting their growth potential in the retail recovery process.”Eternal Beauty has established an omni sales channel network over 400 cities across Chinese Mainland, Hong Kong and Macau. The cooperation with Lane Crawford is an important part of the Group’s retail channel strategy, aiming to enhance the consumer experience and sales conversion by leveraging the prime location and high customer traffic of the premium department store.Photo CaptionEternal Beauty and Lane Crawford debut landmark niche fragrance zone, bringing together four international niche fragrance brands under the concept of a "Luxury Niche Perfume Street". The zone immersively showcasing four distinctive and heritage-rich brands: Atkinsons, Clive Christian, Memo Paris, and SOLFÉRINO.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharingAbout Eternal Beauty Holdings LimitedEternal Beauty Holdings Limited is the largest perfume group (apart from brand-owner perfume groups) in China (including Hong Kong and Macau) in terms of retail sales in 2023. It primarily sells and distributes products procured from third-party brand licensors, and deploys market for these brand licensors, offering such services as brand management, and designing and implementing customized market entry and expansion plans for their brands. The Group boasts large and diversified brand portfolios that include not only perfumes, but also color cosmetics, skincare products, personal care products, eyewear and home fragrances. As at 30 September 2025, it conducted product distribution and market deployment for a total of 74 external brands, including Hermès, Van Cleef & Arpels, Chopard, Albion and Laura Mercier, with products in different pricing tiers and of versatile features that meet the differentiated demands of consumers in Chinese Mainland, Hong Kong and/or Macau. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 中国香水产业领航者颖通控股有限公司（「颖通控股」或「集团」）（股份代号：6883.HK）宣布与顶级奢侈品百货连卡佛达成首度合作，于尖沙咀海运大厦连卡佛内设立首个小众香水限定专区，进一步落实集团聚焦高毛利小众香水品牌的发展策略，并透过顶级零售网络深化高端品牌布局，把握中国内地及香港高端香氛市场持续增长所带来的盈利机遇。​专区云集四大国际高端香氛品牌，以充满欧洲风情的「高级小众香水街」为概念，沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。Clive Christian 及 SOLFÉRINO 更是首度登陆香港，为本地高端消费者带来独家体验，并藉助连卡佛覆盖高消费客群的优质零售网络，有效提升品牌在香港市场的渗透率，进一步将集团旗下品牌引入香港核心高端零售据点，展现集团在渠道拓展与零售策展方面的实力，巩固于高端香氛市场的品牌影响力及长期增长动能。品牌介绍：Atkinsons拥有二百年历史来自英国的「皇室御用香氛品牌」，重塑十九世纪英伦绅士的叛逆与优雅，将历史配方化为现代摩登气息。Clive Christian香港首间典藏级专柜：源自英国伦敦的 Clive Christian 被誉为「世界最奢华的香水之一」，致敬英国皇室贵族经典与顶级奢华工艺传承，彰显无可比拟永恒优雅的底蕴。Memo Paris来自法国的 Memo Paris 以旅行与记忆为灵感，以香气铭记旅途故事，绘制一幅诗情画意的香氛情感地图，将世界景致汇聚于瓶中。SOLFÉRINO首次于香港耀目登场的 SOLFÉRINO 诞生于法国巴黎，灵感源自这座光之城的历史建筑，以精湛工艺诠释法式优雅，创作前卫而富创意的香气。颖通控股执行董事及国际香氛协会主席刘颕贤女士表示：「凭借四十余年的行业经验，颖通积累了敏锐视野、独到品味与深厚专业知识，得以精准甄选契合市场趋势且具备盈利潜力的品牌，并引入蕴藏巨大消费升级动能的大中华市场。我们很高兴与亚洲具影响力的奢侈品百货连卡佛携手，在香港核心奢侈品商圈打造首个小众香水专区，充分发挥颖通在高端香氛品牌运营与零售渠道布局方面的专长。这不仅是集团深化小众香水市场的重要一步，更是我们高端香氛品牌布局策略的具体实践。未来，集团将持续探索与顶级零售伙伴的合作机会，引入更多具高成长潜力的小众品牌，进一步强化集团在高端香氛市场的长期增长动能与可持续盈利能力。」香港香氛市场持续受惠于情绪经济带动，在整体零售业稳步复苏的环境下，展现出相对强韧的增长势头。2025年12月，香港零售业总销货价值按年上升6.6%；而根据市场展望报告预测，2026年香港零售总额有望增长近8%，达到约4,100亿港元，显示本地消费需求正持续回暖。 颖通控股执行董事兼首席执行官林荆女士表示：「近年，体验式零售和情绪消费渐成为零售新潮流，情绪价值在消费决策中的比重明显提升，能否与消费者建立情绪共鸣，正日益成为品牌拓展与产品创新的重要方向。以高端与小众香氛为代表的新兴消费板块，愈来愈多地被视为承载情绪价值与生活方式主张的品类，显示其在零售复苏进程中的增长潜力。」颖通控股已建立覆盖中国内地、香港及澳门逾400个城市的全渠道销售网络，是次与连卡佛的合作为集团零售渠道升级策略的重要一环，旨在透过高端百货的黄金地段与客流量，提升品牌消费体验与销售转化。图片说明颖通控股与连卡佛合作开设首个小众香水专区，云集四大国际高端香氛品牌，以充满欧洲风情的「高级小众香水街」为概念，沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。请通过此链接下载更多高清图片：https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharing关于颖通控股有限公司颖通控股有限公司是中国（包括香港及澳门）最大的香水集团（除品牌所有者香水集团外，按2023年零售额计），主要从事销售及分销从第三方品牌授权商采购的产品及为该等品牌授权商进行市场部署，例如为其品牌设计及实施定制的市场进入及扩张计划。颖通控股拥有庞大且多元化的品牌组合，不仅包括香水，还包括彩妆、护肤品、个人护理产品、眼镜及家居香氛。截至2025年9月30日，颖通控股为合共74个外部品牌进行产品分销及市场部署，包括 Hermès、Van Cleef & Arpels、Chopard、Albion及Laura Mercier，涵盖多元化的定价层次及功能，迎合中国内地、香港及或澳门消费者的差异化需求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com